Publication Name	World Journal of Diabetes
Manuscript ID	95054
Country	Oman

Received	2024-04-01 04:47
Peer-Review Started	2024-04-01 04:47
To Make the First Decision
Return for Revision	2024-05-11 08:11
Revised	2024-05-13 12:38
Second Decision	2024-06-13 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-06-13 07:04
Articles in Press	2024-06-13 07:04
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-06-19 09:32
Typeset the Manuscript	2024-06-28 07:46
Publish the Manuscript Online	2024-08-27 15:11

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Editorial
Article Title	Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy?
Manuscript Source	Invited Manuscript
All Author List	Saeed Mohammadi and Ahmed Al-Harrasi
ORCID	Author(s) ORCID Number Saeed Mohammadi http://orcid.org/0000-0001-9895-8468 Ahmed Al-Harrasi http://orcid.org/0000-0003-0317-8448
Funding Agency and Grant Number
Corresponding Author	Ahmed Al-Harrasi, PhD, Full Professor, Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, PO Box 33, Nizwa 616, Oman. aharrasi@unizwa.edu.om
Key Words	Diabetic cardiomyopathy; Macrophage; Dipeptidyl peptidase-4 inhibitor; Teneligliptin; NLRP3 inflammasome; Glucagon-like peptide-1
Core Tip	Targeting macrophage function could be introduced as a new approach for managing diabetic cardiomyopathy. Chronic hyperglycemia interrupts the balance between pro-inflammatory and anti-inflammatory subtypes of macrophages, promoting inflammation and tissue damage. The dipeptidyl peptidase-4 inhibitors, used for diabetes, might offer cardioprotective benefits by influencing macrophage activity and promoting an anti-inflammatory environment.
Publish Date	2024-08-27 15:11
Citation	<p>Mohammadi S, Al-Harrasi A. Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy? <i>World J Diabetes</i> 2024; 15(9): 1847-1852</p>
URL	https://www.wjgnet.com/1948-9358/full/v15/i9/1847.htm
DOI	https://dx.doi.org/10.4239/wjd.v15.i9.1847

Full Article (PDF)	WJD-15-1847-with-cover.pdf
Full Article (Word)	WJD-15-1847.docx
Manuscript File	95054_Auto_Edited-YJP-Language editing-Webster J-Clear.docx
Answering Reviewers	95054-answering-reviewers.pdf
Audio Core Tip	95054-audio.m4a
Conflict-of-Interest Disclosure Form	95054-conflict-of-interest-statement.pdf
Copyright License Agreement	95054-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	95054-non-native-speakers.pdf
Peer-review Report	95054-peer-reviews.pdf
Scientific Misconduct Check	95054-scientific-misconduct-check.png
Scientific Editor Work List	95054-scientific-editor-work-list.pdf
CrossCheck Report	95054-crosscheck-report.pdf